bromodeoxyuridine has been researched along with n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, Q; Chapman, MS; Hedley, DW; Miner, JN | 1 |
1 other study(ies) available for bromodeoxyuridine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
Article | Year |
---|---|
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Diphenylamine; Enzyme Inhibitors; Humans; Male; MAP Kinase Kinase Kinases; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Signal Transduction; Sirolimus; Sulfonamides | 2010 |